Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity

Daniella C Terenzi,Ehab Bakbak,Hwee Teoh,Aishwarya Krishnaraj,Pankaj Puar,Ori D Rotstein,Francesco Cosentino,Ronald M Goldenberg,Subodh Verma,David A Hess

DOI: https://doi.org/10.1093/cvr/cvae016

IF: 13.081

2024-02-19

Cardiovascular Research

Abstract:Ischaemic cardiovascular diseases, including peripheral and coronary artery disease, myocardial infarction, and stroke, remain major comorbidities for individuals with type 2 diabetes (T2D) and obesity. During cardiometabolic chronic disease (CMCD), hyperglycaemia and excess adiposity elevate oxidative stress and promote endothelial damage, alongside an imbalance in circulating pro-vascular progenitor cells that mediate vascular repair. Individuals with CMCD demonstrate pro-vascular 'regenerative cell exhaustion' (RCE) characterized by excess pro-inflammatory granulocyte precursor mobilization into the circulation, monocyte polarization towards pro-inflammatory vs. anti-inflammatory phenotype, and decreased pro-vascular progenitor cell content, impairing the capacity for vessel repair. Remarkably, targeted treatment with the sodium-glucose cotransporter-2 inhibitor (SGLT2i) empagliflozin in subjects with T2D and coronary artery disease, and gastric bypass surgery in subjects with severe obesity, has been shown to partially reverse these RCE phenotypes. SGLT2is and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have reshaped the management of individuals with T2D and comorbid obesity. In addition to glucose-lowering action, both drug classes have been shown to induce weight loss and reduce mortality and adverse cardiovascular outcomes in landmark clinical trials. Furthermore, both drug families also act to reduce systemic oxidative stress through altered activity of overlapping oxidase and antioxidant pathways, providing a putative mechanism to augment circulating pro-vascular progenitor cell content. As SGLT2i and GLP-1RA combination therapies are emerging as a novel therapeutic opportunity for individuals with poorly controlled hyperglycaemia, potential additive effects in the reduction of oxidative stress may also enhance vascular repair and further reduce the ischaemic cardiovascular comorbidities associated with T2D and obesity. Cardiometabolic chronic disease, defined herein as the combination of T2D and obesity, is associated with vessel dysfunction and cardiometabolic exhaustion of circulating vascular regenerative cells resulting in unrepaired blood vessel damage. Chronic elevation of systemic oxidative stress further contributes to adipose, kidney and endocrine tissue dysfunction, all of which potentiate the development of ischaemic cardiovascular diseases. The pleiotropic cardiorenal protective and weight loss benefits of SGLT2i and GLP-1RA treatments, respectively, present a novel opportunity for combination therapy to abrogate this chronic cardiometabolic cycle and potentially restore progenitor cell-mediated blood vessel repair.

cardiac & cardiovascular systems

What problem does this paper attempt to address?

The main problem this paper attempts to address is: How to restore impaired vascular regeneration capacity in patients with type 2 diabetes (T2D) and obesity through the combined use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA).

Specifically, the paper focuses on the following points:

1. **Vascular Regeneration Impairment**: Patients with T2D and obesity often suffer from cardiovascular diseases such as peripheral artery disease, coronary artery disease, myocardial infarction, and stroke. These diseases are associated with oxidative stress and endothelial damage caused by hyperglycemia and excess fat, leading to an imbalance of circulating pro-vascular progenitor cells, which in turn affects vascular repair capacity.

2. **Regenerative Cell Exhaustion (RCE)**: Patients with T2D and obesity exhibit "regenerative cell exhaustion" (RCE), characterized by excessive mobilization of pro-inflammatory granulocyte precursors, polarization of monocytes towards a pro-inflammatory phenotype, and a reduction in the content of pro-vascular progenitor cells. These factors collectively impair vascular repair capacity.

3. **Therapeutic Effects of SGLT2i and GLP-1RA**: Studies have found that SGLT2i (such as empagliflozin) and GLP-1RA (such as liraglutide) not only reduce blood glucose and weight but also enhance vascular repair capacity by reducing systemic oxidative stress and improving the content of circulating pro-vascular progenitor cells.

4. **Potential of Combined Therapy**: The combined therapy of SGLT2i and GLP-1RA may have a synergistic effect, further reducing oxidative stress and enhancing vascular repair capacity, thereby more effectively reducing ischemic cardiovascular complications in patients with T2D and obesity.

In summary, this paper aims to explore the potential mechanisms and clinical application prospects of combined SGLT2i and GLP-1RA therapy in restoring vascular regeneration capacity in patients with T2D and obesity.